BOSTON SCIENTIFIC CORP (BSX)
NYSE · Instruments & Medical Devices · Surgical & Medical Instruments & Apparatus
- Price
- $44.62
- Day
- -0.67%
- Market cap
- $64.66B
- P/E
- 17.6
Close 2026-09-23.
The company
Our Company Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high-performance solutions to address unmet patient needs and reduce the cost of health care. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.
From Item 1: Our Company.
By product & service
- Interventional Cardiology Vascular Therapies — 23%
- Electrophysiology EP — 17%
- Global Endoscopy Endo Reporting Unit — 14%
- Global Urology and Pelvic Health Reporting Unit — 14%
- Cardiac Rhythm Management — 12%
- Watchman — 10%
- Global Neuromodulation Nm Reporting Unit — 6%
- Interventional Oncology Embolization — 5%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- VANGUARD CAPITAL MANAGEMENT LLC — $4.14B
- STATE STREET CORP — $2.99B
- PRIMECAP MANAGEMENT CO/CA/ — $2.16B
- BlackRock, Inc. — $1.89B
- BlackRock, Inc. — $1.34B
- VANGUARD PORTFOLIO MANAGEMENT LLC — $1.27B
- FMR LLC — $1.24B
- GEODE CAPITAL MANAGEMENT, LLC — $1.21B
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Morano Susan E (Director) bought 2,040 shares at $49.22 on 2026-08-25
- Habiger David C (Director) bought 2,100 shares at $47.59 on 2026-08-05
- Habiger David C (Director) bought 140 shares at $48.59 on 2026-08-04
- Habiger David C (Director) bought 1,042 shares at $48.07 on 2026-08-03
- Mahoney Michael F (Chairman, President & CEO) bought 186,240 shares at $48.33 on 2026-08-03
- LUDWIG EDWARD J (Director) bought 5,000 shares at $45.48 on 2026-07-31
Recent filings
- 8-K — 2026-09-08
- 4 — 2026-09-03
- 4 — 2026-08-26
- 8-K — 2026-08-26
- 4 — 2026-08-12
- 4 — 2026-08-11
- 4 — 2026-08-07
- SCHEDULE 13G/A — 2026-08-06
- 4 — 2026-08-05
- 4 — 2026-08-05